APX3330

DRUG2 trials

Sponsors

Apexian Pharmaceuticals, Inc., Ocuphire Pharma, Inc.

Conditions

CancerDiabetic Macular EdemaDiabetic RetinopathyNPDR - Non Proliferative Diabetic RetinopathyPDR - Proliferative Diabetic Retinopathy

Phase 1

A Study of APX3330 in Patients With Advanced Solid Tumors

CompletedNCT03375086

Apexian Pharmaceuticals, Inc.Cancer

Start: 2018-01-30End: 2019-01-09Updated: 2020-09-07

Phase 2

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

CompletedNCT04692688

Ocuphire Pharma, Inc.Diabetic Macular Edema, Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy +1

Start: 2021-04-08End: 2023-01-25Updated: 2026-06-08

Related Papers

A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in Cancer.

2025-12-191 citations

Abstract 2009: Elucidating the mechanistic effect of targeting Ref-1 redox function on MPNST survival signaling using patient-derived xenolines

Cancer Research2022-06-15

Abstract 1452: Deciphering mechanisms of Ref-1 signaling and its inhibition in aggressive tumor-stroma PDAC models

Cancer Research2021-07-01

Abstract PR01: A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor

Molecular Cancer Therapeutics2019-12-013 citations

A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-2029 citations

Novel first-in-class small molecule targeting APE1/Ref-1 to prevent and treat chemotherapy-induced peripheral neuropathy (CIPN).

Journal of Clinical Oncology2018-11-281 citations